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Abstract
We previously reported on the cross-national epidemiology of ADHD from the first 10 countries in 
the WHO World Mental Health (WMH) Surveys. The current report expands those previous 
findings to the 20 nationally or regionally representative WMH surveys that have now collected 
data on adult ADHD. The Composite International Diagnostic Interview (CIDI) was administered 
to 26,744 respondents in these surveys in high-, upper-middle-, and low-/lower-middle-income 
countries (68.5% mean response rate). Current DSM-IV/CIDI adult ADHD prevalence averaged 
2.8% across surveys and was higher in high (3.6%)- and upper-middle (3.0%)- than low-/lower-
middle (1.4%)-income countries. Conditional prevalence of current ADHD averaged 57.0% 
among childhood cases and 41.1% among childhood subthreshold cases. Adult ADHD was 
significantly related to being male, previously married, and low education. Adult ADHD was 
highly comorbid with DSM-IV/CIDI anxiety, mood, behavior, and substance disorders and 
significantly associated with role impairments (days out of role, impaired cognition, and social 
interactions) when controlling for comorbidities. Treatment seeking was low in all countries and 
targeted largely to comorbid conditions rather than to ADHD. These results show that adult 
ADHD is prevalent, seriously impairing, and highly comorbid but vastly under-recognized and 
undertreated across countries and cultures.
Keywords
ADHD; Attention-deficit/hyperactivity disorder; Comorbidity; Disability epidemiology; 
Impairment; Prevalence; Treatment
Introduction
While most epidemiological studies of the prevalence and correlates of childhood and adult 
attention deficit hyper-activity disorder (ADHD) have taken place in the USA, Australia and 
Western Europe, a recent increase in comparable studies in other parts of the world and the 
publication of several comprehensive reviews (Alhraiwil et al. 2015; Polanczyk et al. 2007; 
Polanczyk and Jensen 2008; Polanczyk et al. 2014; Thomas et al. 2015) make it clear that 
ADHD is coming to be recognized as an important disorder throughout the world given its 
early age-of-onset, strong associations with the subsequent onset and persistence of 
secondary disorders, persistence into adulthood, and strong effects on impaired role 
functioning throughout the life span. A challenge in comparing cross-national results, 
though, is that existing epidemiological studies vary widely in measures, classification 
systems, and data collection procedures. The largest and most systematic effort to address 
these methodological problems to date has been the World Health Organization’s World 
Mental Health (WMH) Survey Initiative, a series of coordinated community epidemiological 
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surveys of the prevalence and burdens of adult mental disorders in countries throughout the 
world (Kessler and Ustun 2008). Adult ADHD was one of the disorders assessed in the 
WMH surveys, while retrospective reports were obtained from adult respondents about 
childhood ADHD. Previous WMH reports have presented data from the first 10 WMH 
surveys on the prevalence and descriptive correlates of childhood and adult ADHD (Fayyad 
et al. 2007), the associations of childhood ADHD with subsequent secondary comorbid 
disorders (Kessler et al. 2011), the predictors of ADHD persistence into adulthood (Lara et 
al. 2009), and the role impairments associated with adult ADHD (de Graaf et al. 2008). The 
current report presents an update on all these topic results based on a doubling of the number 
of countries that have completed WMH surveys since the publication of the earlier WMH 
reports.
Methods and materials
Samples
The WMH surveys are a series of cross-national community epidemiological surveys using 
consistent sampling designs, field procedures, and instruments to facilitate pooled cross-
national analyses of prevalence and correlates of common mental disorders (Kessler and 
Ustun 2008). The countries in the initiative are in no way representative of all countries in 
the world or even within their region of the world, but nonetheless present an unprecedented 
opportunity to examine cross-national consistency and variation in prevalence and correlates 
of mental disorders. The data reported here come from the subset of 20 WMH surveys that 
assessed adult ADHD. The surveys included 11 in countries classified by the World Bank 
(World Bank 2012) as high-income countries (national surveys in Belgium, France, 
Germany, Italy, Netherlands, Northern Ireland, Poland, Portugal, Spain, and the USA along 
with a regional survey in Spain [Murcia]), 5 in countries classified as upper-middle-income 
countries (national surveys in Lebanon and Romania, a survey in all urbanized areas of 
Mexico, and regional surveys in Brazil [Sao Paulo] and Colombia [Medellin]), and 4 in 
countries classified as low-/lower-middle-income (national surveys in Colombia and Iraq, a 
survey in all urbanized areas of Peru, and a regional survey in the People’s Republic of 
China [Shenzhen]). (Table 1) (Colombia was listed as both an upper-middle-and lower-
middle-income country in two different surveys because Colombia’s World Bank rating 
changed between the times of the two surveys.) Each survey was based on a probability 
sample of household residents in the target population using a multistage clustered area 
probability sample design. Response rates ranged from 45.9% (France) to 97.2% (Colombia) 
and had a weighted mean of 68.5% across surveys. A detailed description of sampling 
procedures is presented elsewhere (Heeringa et al. 2008).
Field procedures
Interviews were administered face-to-face in respondent homes after obtaining informed 
consent using procedures approved by local Institutional Review Boards. The interview 
schedule was developed in English and translated into other languages using a standardized 
WHO translation, backtranslation, and harmonization protocol (Harkness et al. 2008). 
Bilingual supervisors from each country were trained and supervised by the WMH Data 
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Collection Coordination Centre to guarantee cross-national consistency in field procedures 
(Pennell et al. 2008).
Interviews were in two parts. Part I, administered to all respondents, assessed core DSM-IV 
mental disorders (n = 90,712 respondents across all surveys). Part II assessed additional 
disorders and correlates. Part II was administered to 100% of Part I respondents who met 
lifetime criteria for any Part I disorder and a probability sub-sample of other Part I 
respondents. ADHD was assessed among respondents in the age range 18–44 in Part II (n = 
26,744). The restriction on the age range was imposed based on a concern about the effects 
of recall bias among older respondents whereby respondents 45 years and older may not 
recall symptoms that they experienced in childhood. Part II respondents were weighted to 
adjust for differential within and between household probabilities of selection, selection into 
Part II, and deviations between the sample and population sociodemographic–geographic 
distributions. More details about WMH sample design and weighting procedures are 
presented elsewhere (Heeringa et al. 2008).
Measures
Diagnostic assessment—Lifetime and current DSM-IV disorders were assessed using 
the WHO Composite International Diagnostic Interview (CIDI) version 3.0 (Kessler and 
Üstün 2004), a fully structured lay-administered interview. Organic exclusion rules and 
hierarchy rules were used in making all diagnoses other than alcohol and drug use disorders, 
where abuse was defined with or without dependence and dependence was assessed only 
among respondents with a history of abuse. No informants other than the respondents were 
interviewed. As detailed elsewhere (Haro et al. 2006), blinded clinical reappraisal interviews 
with the Structured Clinical Interview for DSM-IV (SCID) (First et al. 2002) found 
acceptable-good concordance between DSM-IV/CIDI diagnoses and DSM-IV/SCID 
diagnoses in the four WMH countries where clinical reappraisal studies were administered 
(France, Italy, Spain, USA). Retrospective reports were used to date age-of-onset of each 
lifetime disorder using probing methods that have been shown experimentally to improve 
accuracy of recall (Knäuper et al. 1999).
The CIDI retrospective assessment of childhood ADHD was based on the Diagnostic 
Interview Schedule (DIS) (Robins and Helzer 1985). Respondents with symptoms of 
childhood ADHD were asked whether they still had problems with inattention or 
impulsivity–hyperactivity and, if so, were asked about impairments due to these symptoms. 
A probability subsample of 154 such respondents in the US sample was administered 
blinded clinical follow-up interviews to assess DSM-IV adult ADHD using the validated 
form of the Adult ADHD Clinical Diagnostic Scale (ACDS) Version 1.2 (Adler and Cohen 
2004; Adler and Spencer 2004), a semi-structured clinical research diagnostic interview for 
adult ADHD. This clinical reappraisal survey is described in more detail elsewhere (Kessler 
et al. 2006).
Logistic regression analysis was used in the ACDS clinical reappraisal sample to predict 
DSM-IV/ACDS diagnoses of adult ADHD from CIDI symptom questions. Diagnostic 
classification accuracy was good, with area under the receiver operating characteristic curve 
(AUC) of .86. Based on this result, the method of multiple imputation (MI) (Rubin 1987) 
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was used to assign imputed clinical diagnoses of adult ADHD to respondents in all WMH 
surveys based on the coefficients in the prediction equation in the US clinical reappraisal 
sample. This approach implicitly assumes that the association between CIDI responses and 
clinical diagnoses is constant across countries. If this assumption is incorrect, the results will 
be biased. It would have been preferable to implement clinical reappraisal studies in other 
countries, but this was not possible.
The statistical details of the MI method are discussed elsewhere (Kessler et al. 2006). The 
important points to emphasize here are that MI generates unbiased prevalence estimates 
under the model, that individual-level estimates have good accuracy when, as in this case, 
AUC is high, and that a simulation that is part of the MI approach adjusts estimates of 
standard errors for the effects of classification error due to imperfect imputation. The 
imputation equation used here was somewhat less refined than in the earlier US study 
because not all countries included all predictors used in the US imputation equation.
Role impairments—The role impairments associated with adult ADHD were assessed 
using a 19-item modified version of the WHO Disability Assessment Schedule 2.0 
(WHODAS; Üstün et al. 2010), a validated self-report instrument that assesses difficulties in 
four domains of role functioning over the past 30 days before interview: cognition 
(communicating and understanding); mobility (moving and getting around); self-care 
(personal hygiene, dressing, eating, living alone); and social interaction. The assessment 
includes a series of parallel questions about frequency and severity of impairment (rated 
none, mild, moderate, and severe) in each role domain. We focus on dichotomous 
classifications for whether respondents had clinically meaningful impairments in each of 
these four domains. In addition, the WMH surveys included a question about the number of 
days out of the past 30 when respondents were totally unable to carry out their normal 
activities due to problems with their physical or mental health. We dichotomized this 
variable to consider respondents who reported any versus no days out of role.
Treatment for emotional problems—All Part II respondents were asked whether they 
received treatment for “problems with your emotions or nerves or your use of alcohol or 
drugs” in the 12 months before interview from each of four different treatment sectors: 
mental health specialty (psychiatrist, psychologist, social worker or counselor in a mental 
health specialty setting, use of a mental health hotline); general medical (primary care 
doctor, other general medical doctor, nurse, any other health professional); human services 
(religious or spiritual advisor, social worker or counselor in any setting other than a specialty 
mental health setting); and complementary-alternative medicine (CAM; any other type of 
healer such as a chiropractor or native healer or participation in an internet support group or 
self-help group).
Analysis methods
Prevalence of ADHD and associations of ADHD with sociodemographics, comorbid DSM-
IV/CIDI disorders, treatment, and role impairment were estimated using MI cross-
tabulations. Sociodemographic correlates of ADHD onset and persistence into adulthood 
were estimated in pooled (across surveys) MI logistic regression analyses. It is noteworthy 
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that most of the correlates considered (educational level, employment status, marital status, 
income) were assessed as of the time of interview, which means that these variables cannot 
be thought of as temporally prior predictors of the onset or persistence of ADHD, but only 
as descriptive correlates. We also used pooled MI logistic regression analyses to estimate 
comorbidities and associations of ADHD with role impairment. In each of these models, we 
included dummy control variables for surveys, estimating each model separately in the ten 
MI replications and pooling results to get averaged estimates of logistic regression 
coefficients and design-adjusted estimates of standard errors. These coefficients and 
standard errors were exponentiated for ease of interpretation and are reported as odds ratios 
(ORs) with their 95% confidence intervals (95% CIs). The design-based Taylor series 
method (Wolter 1985) implemented in the SAS software system (SAS Institute Inc. 2008) 
was used to adjust for the weighting and clustering of observations. Design-based MI Wald 
Chi-square tests were used to evaluate the significance of predictor sets.
Given the strong temporal priority found between ADHD and comorbid DSM-IV/CIDI 
disorders, we also examined the extent to which ADHD predicted the subsequent first onset 
of the other disorders using the retrospective reports in the WMH surveys about age-of-onset 
and recency of each disorder. We made two distinctions in these analyses: between 
respondents who had an AD-only childhood symptom profile (i.e., the respondent had 6–9 
of the 9 DSM-IV symptoms of inattention but fewer than 6 of the 9 symptoms of 
hyperactivity–impulsivity) and those who had a childhood HD symptom profile (i.e., the 
respondent had 6–9 of the 9 DSM-IV symptoms of hyperactivity–impulsivity with or 
without symptoms of inattention); and between onsets of secondary disorders associated 
with lifetime ADHD cases that were active versus remitted (based on retrospective reports 
about persistence of lifetime ADHD and age-of-onset of temporally secondary disorders). 
These specifications were examined using a discrete-time person-year survival analysis 
framework with person-year as the unit of analysis and a logistic link function (Singer and 
Willett 1993). ADHD was coded as time-varying dummy predictor variables distinguishing 
active and remitted AD-only and HD cases. These models included dummy control variables 
for surveys and person-years, estimating each model separately in the ten MI replications 
and pooling results to get averaged estimates of coefficients and design-adjusted estimates of 
standard errors. As in the person-level logistic regression models, these coefficients and 
standard errors were exponentiated and are reported as odds ratios (ORs) with their 95% 
CIs, again using the Taylor series method (Wolter 1985) to adjust for the weighting and 
clustering of observations.
Results
ADHD prevalence in childhood and persistence into adulthood
Prevalence of DSM-IV/CIDI ADHD in childhood averaged 2.2% across the surveys, but had 
an extremely wide range (0.1–8.1%) and inter-quartile range (0.9–2.9%) (Table 2). 
Prevalence was significantly related to country income level, with prevalence of 3.3% in 
high, 2.2% in upper-middle-, and 0.6% in low-/lower-middle-income countries ( , 
p < .001). Subthreshold childhood ADHD (4–5 rather than 6+ AD and/or HD symptoms in 
addition to other required criteria) was even more prevalent (3.7% across countries; 4.7% in 
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high-, 4.0% in upper-middle-, and 2.2% in low-/lower-middle-income countries; , p 
< .001). Conditional prevalence of current (at the time of interview) adult ADHD averaged 
57.0% across surveys among respondents with a history of childhood ADHD (56.2% in 
high-, 54.1% in upper-middle-, and 71.7% in low-/lower-middle-income countries; , 
p = .30) and 41.1% among respondents with a history of subthreshold childhood ADHD 
(36.9% in high-, 46.8% in upper-middle-, and 45.9% in low-/lower-middle-income 
countries; , p = .14). Current prevalence of adult ADHD in the total sample averaged 
2.8% across surveys, again with high range (0.6–7.3%) and inter-quartile range (1.8–4.1%) 
and higher prevalence in high-income countries (3.6%) and upper-middle-income (3.0%) 
than low-/lower-middle-income (1.4%) countries ( , p < .001). Surprisingly, these 
results suggest that adult ADHD is more prevalent than childhood ADHD and that this 
pattern is true consistently in high (3.6 vs. 3.3%)-, upper-middle (3.0 vs. 2.2%)-, and low-/
lower-middle (2.8 vs. 2.2%)-income countries. We return to this observation in the 
discussion section of the paper.
Sociodemographic correlates
Pooled across surveys, childhood ADHD was significantly more common among men than 
women (OR 1.6; 95% CI 1.3–2.0) and positively associated with level of educational 
attainment ( , p < .001) due to a significantly higher prevalence among respondents 
who, at the time of interview, had less than a college education compared to college 
graduates (ORs in the range 1.5–2.4) (Table 3). In comparison, childhood ADHD was not 
significantly associated with respondent age at the time of interview (which, as noted above, 
was in the age range 18–44), current (at the time of interview) employment status, current 
marital status, or current income. The same basic sociodemographic patterns were found 
with subthreshold childhood ADHD with the exception that prevalence was inversely 
associated with age at interview ( , p < .001). Persistence of childhood ADHD into 
adulthood (i.e., current prevalence) among childhood cases, in comparison, was significantly 
associated with respondent employment status (employed vs. all others; , p = .001) 
due to comparatively low persistence among the currently employed. None of the 
sociodemographics was significantly related to adult ADHD among subthreshold childhood 
cases
The strength of associations of the sociodemographics with unconditional prevalence of 
adult ADHD was, in effect, a weighted combination of the associations with childhood 
ADHD in the total sample and adult persistence among childhood threshold and 
subthreshold cases. Unconditional adult prevalence was significantly higher among men 
than women (OR 1.6; 95% CI 1.3–1.9) and significantly associated with young age 
( , p < .001), less than college educational attainment ( , p < .001), and 
being unmarried ( , p = .004). The higher prevalence among men than women was 
due to the significantly elevated risk of childhood ADHD noted above. The significant 
inverse association of age with current adult ADHD was due to several component 
associations that can be seen in other columns of the table. These include a significant 
inverse association of age with subthreshold childhood ADHD, an insignificant trend inverse 
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association of age with childhood threshold ADHD, and a significant trend inverse 
association of age with adult persistence of ADHD among childhood cases. The significant 
association of current adult ADHS with being unmarried was due to a significantly elevated 
odds of childhood threshold ADHD with being previously married at the time of interview 
(OR 1.4; 95% CI 1.1–1.9) in addition to insignificant trend associations of being previously 
married and never married with persistence among childhood threshold and subthreshold 
cases.
Comorbidities of ADHD with other DSM-IV/CIDI disorders
Twelve-month adult ADHD was significantly and positively comorbid with 12-month 
prevalence of other DSM-IV/CIDI disorders considered in the WMH surveys (Table 4). ORs 
were in the range between 2.5 (major depressive disorder) and 15.0 (oppositional defiant 
disorder) with individual comorbid disorders, 4.4 with a summary variable of having any 
comorbid disorder, and increasing ORs with number of comorbid disorders (3.0 with exactly 
one comorbid disorder, 6.2 with exactly two, and 9.6 with three or more; , p < .001). 
Retrospective age-of-onset reports were used to date temporal priorities between onset ages 
of ADHD and comorbid disorders. Given the early age-of-onset of ADHD required in DSM-
IV, it is not surprising that we found ADHD to be the temporally primary disorder in the vast 
majority of cases of comorbidities involving mood disorders (86.0–94.0%), anxiety 
disorders other than specific phobia (70.5–90.2%), and substance use disorders (94.8–
99.1%). Specific phobia was the only comorbid disorder that was more likely to be 
temporally primary than ADHD (specific phobia first in 53.1% of cases, ADHD first in 
29.1%, and same year in the remaining 17.8%).
Given the strong temporal priority of ADHD over the vast majority of comorbid disorders, 
we examined the extent to which ADHD predicted the subsequent first onset of the other 
disorders assessed in the surveys. As noted above in the section on analysis methods, we 
distinguished between respondents who had (1) AD-only versus HD (with or without AD) 
childhood symptom profiles in order to see whether those profiles are differentially 
associated with the subsequent onset of temporally secondary disorders. Also, we 
distinguished between active and remitted ADHD cases in order to determine whether the 
ORs of secondary disorders occurring decrease significantly with the remission of ADHD. 
In initial models, we also evaluated the significance of the difference between active and 
remitted ADHD depending on whether the childhood ADHD had an AD-only or HD 
symptom profile. However, as this interaction was never significant ( , p = .88−.
07), we focused on the coefficients in the additive model (Table 5). Three broad patterns of 
results are noteworthy. First, all but one of the ORs for secondary disorders associated with 
remitted ADHD were elevated (ORs = 1.1–2.7, with a median of 1.6 and inter-quartile range 
of 1.2–2.0) and nearly half were statistically significant ( , p = .036–< .001). 
Second, the odds of secondary disorders associated with active ADHD were consistently 
elevated relative to those associated with remitted ADHD (ORs = 1.2–4.6) and nearly two-
thirds of these ORs were statistically significant ( , p = .041–< .001). Third, the 
ORs associated with the AD-only subtype did not differ meaningfully from those associated 
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with the HD subtype, with each of the two having the same median (1.6) and very similar 
inter-quartile ranges (1.1–2.0 for AD-only; 1.2–2.2 for HD).
Disability in 12-month ADHD
Respondent reports of 30-day disability in role functioning based on the WHO-DAS suggest 
that people with adult ADHD are considerably more likely to have disability in cognition 
(21.8%) than in self-care (4.8%), social interactions (10.8%), or mobility (15.5%) (Table 6). 
Controlling for sociodemographics (age, sex, education, employment status, marital status, 
income), respondents with current adult ADHD have significantly elevated odds of all these 
outcomes. Odds ratios for these outcomes are between 3.8 (95% CI 2.9–4.8) for cognition 
and 2.1 (95% CI 1.4–3.3) for self-care. Respondents with current ADHD are also 
significantly more likely than other respondents to report at least 1 day out of role in the 30 
days before interview due to health problems (OR 2.6; 95% CI 2.1–3.3). These significant 
associations are to some extent due to comorbid disorders rather than to ADHD, as indicated 
by the fact that the ORs all attenuate when controls are introduced for 12-month comorbid 
disorders. Nonetheless, all but one of the ORs remain significantly elevated in the range 1.5–
2.1 in the latter models, the exception being an insignificant association of current ADHD 
with disability in self-care.
Treatment of 12-month ADHD
Roughly one-fifth (21.8%) of respondents with 12-month ADHD received some treatment 
for mental health problems in the 12 months before interview (Table 7). This treatment rate 
was significantly and positively related to country income level (28.8% in high-, 15.5% in 
upper-middle-, and 6.8% in low-/lower-middle-income countries; , p < .001). In 
high-income countries, the majority of these patients were treated either in the mental health 
specialty sector (15.9% of all cases) or the general medical sector (17.9%). The proportions 
treated in these two sectors were similar to each other and considerably higher than the 
proportions treated in either the human services (4.9%) or CAM (4.4%) sectors. In upper-
middle-and low-/lower-middle-income countries, in comparison, patients were considerably 
more likely to be treated in the mental health specialty sector (9.8% in upper-middle- and 
5.0% in low-/lower-middle-income countries) than the general medical section (4.9% in 
upper-middle- and 0.6% in low-/lower-middle-income countries), with much smaller 
proportions of cases treated in the human services or CAM sectors (0.7–3.1% in upper-
middle- and 0.3–1.6% in low-/lower-middle-income countries).
Two other observations about the 12-month treatment data are noteworthy. First, the sum of 
the proportions of cases treated in each of the four service sectors considered in the WMH 
surveys is roughly 50% higher in high-income countries (43.1% [i.e., 17.9% + 15.9% 
+ 4.9% + 4.4%]) than the proportion of cases with any treatment in one or more of those 
sectors (28.8%). This means that the average person with 12-month ADHD in high-income 
countries who received treatment for mental health problems in the past 12 months was seen 
in 1.5 service sectors. This average is considerably lower in upper-middle (1.2 service 
sectors)- and low-/lower-middle (1.1 service sectors)-income countries. Previous WMH 
analyses have shown that this pattern of obtaining care for emotional problems in multiple 
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service sectors in high-income countries is typical of people with a wide range of other 
DSM-IV disorders and is not unique to ADHD (Wang et al. 2007).
Second, 12-month treatment specifically for ADHD among respondents with 12-month 
ADHD (shown in the last column of the table) was dramatically lower than 12-month 
treatment for any emotional problems among the same respondents (3.3 vs. 21.8%). This 
same pattern was found in high (5.1 vs. 28.8%)-, upper-middle (1.4 vs. 15.5%)-, and low-/
lower-middle (0.0 vs. 6.8%)-income countries. It is noteworthy that the respondents with 12-
month ADHD in this table include both those with and without other comorbid disorders. 
The finding that the vast majority of treatment is for other disorders is consistent with the 
finding that a substantial part of the impairment of respondents with adult ADHD is 
associated with comorbid disorders, although it is noteworthy that odds of serious 
difficulties with cognition among adults with ADHD are 2.1 of those other respondents after 
adjusting for comorbid conditions. This observation might mean that many people do not 
interpret serious difficulties with cognition as mental problems requiring treatment by a 
mental health professional. Although the WMH surveys did not ask about this matter, 
answers might be valuable in helping to craft public education messages to attract adults 
with ADHD into treatment. Be that as it may, the result suggests that the vast majority of 
adults with ADHD who are in treatment also have some other comorbid mental disorders 
that are the focus of treatment, although our analysis made no attempt to distinguish 
subsamples of respondents with pure and comorbid ADHD or to determine which comorbid 
disorders were most likely to be the presenting complaints. A question also can be raised as 
to how often the treating clinicians are aware that these patients have comorbid ADHD. 
These are all important questions that should be the focus of attention in future studies.
Discussion
Several limitations of the WMH data are noteworthy. The most obvious one is that adult 
ADHD was estimated from an imputation model rather than directly. As noted above in the 
section on measures, this approach generates unbiased prevalence estimates with good 
precision under the model when, as in our case, AUC is high and the population to which 
results are extrapolated are equivalent to the population in which the imputation was 
calibrated. But it is important to note that calibration was carried out only in the USA, which 
was an outlier in terms of prevalence, raising questions about the accuracy of the diagnostic 
threshold in other countries. Given that we have no guarantee that the model holds in all 
WMH countries, caution is consequently needed in interpreting results regarding prevalence 
estimates. Another feature of the multiple imputation method is that estimates of 
associations with outcomes are attenuated due to the inclusion of imputation error even 
when this error is random. This means that the results reported here on the associations of 
adult ADHD with secondary comorbid disorders and disability are likely to be conservative; 
that is, that the true associations are likely to be larger than those estimated here.
It is clear from the above comments that it would be valuable to have a practical screening 
scale that is validated across many countries to assess adult ADHD rather than rely on 
imputation. The WMH collaborators have developed a screening scale of this sort based on 
follow-up analyses of WMH respondents in the USA (Kessler et al. 2005), and this 
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screening scale has been validated in a number of countries (e.g., Lozano et al. 2016; Morin 
et al. 2016; Sjolander et al. 2016). Based on the good performance of the scale in these 
independent validation studies, an updated DSM-5 version of the scale is being developed 
and will be used in future WMH surveys to avoid the need to continue using imputation to 
estimate prevalence of adult ADHD. For now, though, caution is needed in interpreting 
cross-national prevalence estimates for the existing WMH surveys and more work is needed 
to investigate possible substantive and methodological explanations for the large cross-
national difference in prevalence estimates reported here. Also, it has to be understood that 
the associations reported here of other variables with adult ADHD are likely to be lower-
bound estimates due to the attenuation introduced by the use of multiple imputation.
Another limitation of the current study is that childhood ADHD was assessed 
retrospectively, although concern about recall bias is limited somewhat by the fact that we 
restricted these retrospective questions to respondents no older than 44. But then, this 
restriction introduces another limitation that estimates are not available for respondents older 
than 44 years of age. Another limitation is that all diagnoses were based on fully structured 
lay diagnostic interviews rather than semi-structured clinical research diagnostic interviews. 
Concerns about these limitations are lessened to some degree by the fact that clinical 
reappraisal studies carried out in a number of WMH countries documented generally good 
concordance between diagnoses based on the CIDI and independent clinical diagnoses (Haro 
et al. 2006) based on blinded SCID clinical reappraisal interviews (First et al. 2002). 
However, these clinical reappraisal interviews were administered only in a minority of 
WMH countries, so some uncertainty still exists in the extent to which the favorable results 
generalize to all countries. Additionally, recall bias could lead to underreporting the number 
of childhood ADHD symptoms. We addressed this possibility by including and analyzing 
retrospective reports of subthreshold ADHD. With the change of the age-of-onset 
requirement from DSM-IV to DSM-5 (from 7 to 12 years), many of the respondents 
classified as subthreshold cases would have been threshold cases (due to ease of recall of 
symptoms around 12 years of age as opposed to 7 years of age).
Within the context of these limitations, the results reported here build on previous evidence 
about the cross-national epidemiology of ADHD in a number of ways. The most basic of 
these involves prevalence estimates. Population prevalence estimates for childhood ADHD 
have varied widely in previous epidemiological surveys, from less than 1% to over 20%, but 
with a central tendency of 4–6%. A recent quantitative analysis of worldwide studies 
reported pooled current prevalence estimates of 6.5% for children and 2.7% for adolescents 
(Polanczyk et al. 2007). The WMH retrospective estimate of 3.3% in high-income countries 
is intermediate between these two estimates, while the estimate of 2.2% in upper-middle-
income countries is lower and the estimate of 0.6% in low-/lower-middle-income countries 
substantially lower than the lower bounds of these estimates.
Much less evidence exists on the population prevalence of adult ADHD. Early studies 
suggested that prevalence is low based on evidence of low adult persistence in studies that 
followed patients who were treated for ADHD as children into adulthood (Faraone et al. 
2006; Hill and Schoener 1996), but there are a number of obvious methodological flaws with 
such studies (Mannuzza et al. 2003; Sawilowsky and Musial 1988). General population 
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screening studies subsequently carried out found much higher prevalence estimates, with a 
meta-analysis estimating average prevalence to be 2.5% (Simon et al. 2009) and subsequent 
community surveys reporting results generally consistent with this estimate: 5.8% in Brazil 
(Polanczyk et al. 2010), 3.0% in France (Caci et al. 2014), 4.7% in Germany (de Zwaan et 
al. 2012), 1.3–4.6% (threshold–subthreshold) in Hungary (Bitter et al. 2010), and 1.1% in 
South Korea (Park et al. 2011). The WMH prevalence estimate of 2.8% is very similar to the 
average estimate in the meta-analysis (which, importantly, did not include any of the WMH 
surveys in the review), although the WMH series includes a much wider range of countries 
and, as with childhood ADHD, finds a strong association between country income level and 
prevalence.
One striking result of our prevalence analysis is that the estimated prevalence of adult 
ADHD is higher than that of childhood ADHD. This is true because a substantial proportion 
of adult threshold cases were subthreshold childhood cases according to retrospective 
reports. As one might expect, transition probabilities for becoming an adult case were higher 
for childhood threshold than subthreshold cases, but the fact that there were so many 
childhood subthreshold cases and the fact that the transition probabilities to adult cases were 
relatively substantial for those subthreshold childhood cases combine to result in a 
substantial proportion of adults with ADHD reporting sub-threshold ADHD in childhood.
Previous prospective studies that focused on follow-up of childhood cases into adulthood are 
unable to evaluate the possibility that many adults with ADHD had sub-threshold symptoms 
in childhood, as the denominator population for these studies consisted of patients who had 
threshold ADHD in childhood. It would be valuable for prospective community-based 
research to investigate this issue by following epidemiological samples of children who were 
classified as having either threshold or sub-threshold ADHD in community surveys or 
school surveys (e.g., Green et al. 2010) into adulthood to determine whether or not the 
retrospective WMH results hold up prospectively. Another possibility is that this pattern in 
the WMH data might be due to downward recall bias about the severity of childhood 
symptoms among adults with threshold ADHD. It is noteworthy, though, that another related 
issue is that a higher proportion of subthreshold childhood cases will become threshold cases 
in adulthood when DSM-5 diagnostics are used, as DSM-5 requires only 5 symptoms of 
either AD or HD for a diagnosis of adult ADHD compared to 6 in DSM-IV and 6 for 
childhood cases in both DSM-IV and DSM-5.
By combining retrospectively recalled threshold and subthreshold childhood ADHD in the 
total sample (2.2 and 3.7% respectively), the current rate of 2.8% of adult ADHD reflects a 
persistence rate of 47.4%. Since we did not measure subthreshold adult ADHD, this 
persistence rate is likely to be an underestimate of the true persistence of ADHD from 
childhood into adulthood. Recent community cohort studies have suggested that there may 
be cases of “adult onset” ADHD among individuals without a prior history of ADHD in 
childhood (Agnew-Blais et al. 2016; Caye et al. 2016a; Moffitt et al. 2015). As the CIDI did 
not inquire about new onset ADHD in adulthood among respondents who did report at least 
subthreshold ADHD in childhood, our reported prevalence may therefore underestimate the 
total current prevalence of adult ADHD.
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It is unclear whether the association of ADHD prevalence with country income level reflects 
differences in true prevalence, differential recall, differential validity of the CIDI questions 
across countries, or some combination of these factors. One strong possibility is that 
objectively assessed inattention and hyperactivity–impulsivity might be less impairing in 
lower-income than higher-income countries given that these symptoms might interfere less 
with the role demands of people in the former than latter countries. Given the very strong 
cross-national gradient and the plausibility of this possibility, it would be valuable to carry 
out a cross-national comparative analysis that used objective performance-based 
neurocognitive tests to evaluate prevalence of the cognitive deficits underlying adult ADHD 
rather than relying only on self-report assessments. It is noteworthy in this regard that 
performance-based neurocognitive tests have been used in a number of recent studies of 
adult ADHD (e.g., Dehili et al. 2013; Micoulaud-Franchi et al. 2016; Surman et al. 2015) 
and could be used in parallel in community surveys using recently developed technology for 
administering such tests in web-based surveys (www.manybrains.net). It is important to note 
in this regard, though, that the neurocognitive tests studied in adult ADHD up to now have 
been heterogeneous, in many cases only weakly correlated with each other, and non-specific 
for adult ADHD, making it unclear whether this line of research has yet progressed 
sufficiently to warrant implementing such tests in large-scale cross-national community 
epidemiological surveys.
Previous research has also studied sociodemographic correlates of ADHD. Perhaps the most 
consistently documented correlate is sex, with prevalence consistently higher among boys 
than girls and a higher relative prevalence of the predominantly inattentive subtype among 
girls than boys (Rucklidge 2010). Although earlier estimates indicated a male-to-female 
ratio of 9:1, a subsequent meta-analysis concluded that the true prevalence ratio is closer to 
2.45:1 in non-referred community samples (Polanczyk and Jensen 2008). This finding 
suggests that previously reported higher ratios may have been a function of referral or 
treatment bias, as it is known that a higher proportion of boys than girls with ADHD receive 
treatment (Derks et al. 2007). The WMH OR of 1.6 for childhood ADHD among boys/girls 
was somewhat lower than that average. We also found the same OR for adult ADHD due to 
the absence of a significant sex difference in persistence of childhood ADHD into 
adulthood. This finding is consistent with a recent meta-analysis (which, it should be noted, 
included the results of an early WMH analysis of the predictors of persistence of childhood 
ADHD into adulthood based on our first 10 surveys [Lara et al. 2009]), which failed to find 
a significant gender difference in persistence of ADHD into adulthood (Caye et al. 2016b).
Age is a second sociodemographic characteristic that has been examined in studies of 
ADHD prevalence. Meta-analysis finds that this association is negative (Simon et al. 2009), 
a result that we replicate in the WMH surveys despite the fact that the age range of our 
sample was truncated (18–44). Other commonly studied correlates are various indicators of 
socioeconomic status (SES). Although the associations of childhood ADHD with these 
correlates are confounded in treatment samples by selection bias, we would expect an 
inverse association with parental SES by virtue of the high heritability of childhood ADHD 
(Posthuma and Polderman 2013) along with an association of ADHD with low 
socioeconomic attainment (Polderman et al. 2010). Meta-analysis shows, consistent with 
this expectation, that parental SES is inversely related to childhood ADHD, with children 
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from low-SES families having an ADHD prevalence close to twice that of other children 
(Russell et al. 2016).
The WMH data focused on respondent SES rather than parental SES. We found that while 
both threshold and sub-threshold childhood ADHD were associated with significant 
reductions in odds of completing college, persistence of childhood ADHD into adulthood 
was not associated with educational attainment. The significant association of childhood 
ADHD with reduced educational attainment is consistent with the results of a meta-analysis 
(Polderman et al. 2010), but we are unaware of any previous research on educational 
attainment and persistence of childhood ADHD into adulthood. It is conceivable that low 
educational attainment is influenced by childhood but not adult ADHD, while level of 
educational attainment among individuals who have completed their education has no 
influence on the course of ADHD. A more perplexing finding is that we failed to find a 
significant association between respondent family income per family member and adult 
ADHD. This result is inconsistent with other evidence suggesting that adult ADHD is 
associated with low family income (Martel 2013). The reason for this discrepancy between 
the WMH results and the results of earlier studies is unclear.
Finally, we found that respondents with adult ADHD are significantly less likely than other 
respondents to be currently married due to an elevated odds of being previously married. 
This finding is consistent with previous research showing that adult attention deficits are 
elevated among people who are divorced (Bouchard and Saint-Aubin 2014). Our finding of 
high comorbidity in ADHD is consistent with much previous research (Babcock and 
Ornstein 2009; Karlsdotter et al. 2016; Mao and Findling 2014), although it is unclear from 
these data whether ADHD is a causal risk factor or a noncausal risk marker. Our finding that 
respondents with remitted ADHD continue to have elevated risk of subsequent first onset of 
several other disorders argues indirectly for ADHD being a noncausal risk marker, but the 
even more consistently significant elevated odds of secondary disorders associated with 
active than remitted ADHD raise the possibility that ADHD might also be a causal risk 
factor for secondary disorders. This issue is becoming one of increasing public health 
importance, as interest grows in focusing on treatment of childhood ADHD as a secondary 
prevention strategy for downstream disorders. Research in this area is coming to recognize 
that a number of mediators and moderators of the presumed effects of ADHD on secondary 
disorders might exist that represent alternative targets for preventive intervention (Molina 
and Pelham 2014). Our retrospective finding that individuals with remitted ADHD have the 
same significantly elevated risk of some subsequent secondary disorders such as alcohol use 
disorder as those with active ADHD could be of value here in leading a recognition that 
history of childhood ADHD (i.e., whether or not still active) is a risk marker for subsequent 
onset of alcohol abuse (Tuithof et al. 2012).
Our results regarding role impairments are also consistent with much previous research in 
showing that adult ADHD is associated with substantial impairments in productive role 
functioning (Kupper et al. 2012), social role functioning (Bouchard and Saint-Aubin 2014), 
and most strongly in cognitive functioning (Ivanchak et al. 2012). However, we also showed 
that substantial proportions of these associations are more proximally due to comorbid 
mental disorders. Our analysis did not distinguish between mediation effects (e.g., ADHD 
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causes secondary comorbid disorders that, in turn, cause role impairments) or synergistic 
effects in which the conjunction of ADHD and comorbid disorders is associated with a level 
of impairment that is meaningfully different from the level expected based on an additive 
model. More complex analyses than those carried out here would be required to distinguish 
these possibilities. Furthermore, given the evidence that remitted ADHD often predicts 
subsequent onset of secondary disorders, a question can be raised whether some unmeasured 
biological and/or environmental determinants of both ADHD and later-onset disorders might 
account for the impairments associated with ADHD. An investigation of this possibility is 
beyond the scope of this report. However, we know from experimental research on the 
effects of ADHD treatment on objective performance data (e.g., simulated driving tests) that 
at least some part of the association between adult ADHD and role performance is due to a 
direct and modifiable causal effect of ADHD (Biederman et al. 2012), implying that if these 
role impairments, which are known to remit with the remission of ADHD, played a part in 
predicting subsequent onset of temporally secondary disorders, we would expect that risk of 
these disorders would return to their level in the general population with the remission of 
ADHD. That the WMH results suggest that this risk does not return to the population level 
after ADHD remission consequently implies that factors other than the impairment caused 
by ADHD account for the associations of remitted ADHD with subsequent onset of 
temporally secondary disorders.
Our results regarding 12-month adult ADHD treatment, finally, are broadly consistent with 
much other research in showing that only a minority of people with mental disorders obtain 
treatment and that this treatment rate is lower in less developed than developed countries 
(Wang et al. 2007). Other WMH research on treatment seeking for mental disorders has 
shown that the most important barrier is failure to recognize that the symptoms of the 
disorder constitute evidence of an “illness” that could profit from treatment (Andrade et al. 
2014). Not only ADHD but also other disorders with symptoms that are, in effect, extreme 
versions of normal experiences that either begin in childhood (e.g., extreme shyness in social 
phobia) or develop slowly over time (e.g., extreme worry in generalized anxiety disorder) 
have this profile of low treatment seeking for the disorder (ten Have et al. 2013) and the 
majority of patients are in treatment for a comorbid disorder that is more readily recognized 
as a condition needing treatment (e.g., depression, alcohol abuse). This lack of awareness 
has been noted in the past and has led to calls for increased public and professional training 
on how to diagnose adult ADHD (Asherson et al. 2012). Our results suggest strongly that 
training programs of this sort are needed.
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